TissueTech is a leading private regenerative medicine company with a specialized focus on tissue from the amniotic membrane and umbilical cord, with wide ranging clinical applications across ophthalmology, wound care, and orthopedics.
TissueTech is a leading player that pioneered the use of amniotic tissue and established the market. The company plans to gain market leadership through regulatory driven shifts to create differentiation and barriers to entry. Regenerative medicine is a fast growing sector where EW Healthcare Partners has substantial prior experience, including LifeCell, CBR, Bioventus and AxoGen. EW will add value by strengthening board and management, optimizing the commercial infrastructure, and financing clinical trials to obtain FDA approvals that will create sustainable competitive advantages and barriers to entry.